喀斯瑪商城-第三方B2B電子商務(wù)平臺(tái)

<tr id="k02ee"></tr>

Phospho-VEGF Receptor 2 (Tyr951) (15D2) Rabbit mAb

商城價(jià)：登錄可見

品牌：CST/賽信通

貨號(hào)：4991T

規(guī) 格：

運(yùn)費(fèi)：登錄后可查看運(yùn)費(fèi)

DeepBio得分:

DeepBio得分是基于文獻(xiàn)引用次數(shù)，影響因子，文獻(xiàn)新近度等因素計(jì)算的客觀產(chǎn)品評(píng)級(jí)，得分越高表明該產(chǎn)品經(jīng)過越可靠的實(shí)驗(yàn)驗(yàn)證，質(zhì)量可信度越高

1家供應(yīng)商在售
商品名稱	規(guī)格	代理級(jí)別	價(jià)格	運(yùn)費(fèi)	供應(yīng)商	購(gòu)買
CST 4991T Phospho-VEGF Receptor 2(Tyr951)(15D2) Rabbit mAb 交貨周期:部分現(xiàn)貨，期貨3-4周左右，優(yōu)質(zhì)售后	20μl	經(jīng)銷	登錄可見	-	上海優(yōu)寧維生物科技股份有限公司	- + 立即購(gòu)買庫(kù)存：999

產(chǎn)品詳情

文獻(xiàn)引用

文獻(xiàn)圖片

實(shí)驗(yàn)數(shù)據(jù)

應(yīng)用：W, IHC-P
Vascular endothelial growth factor receptor 2 (VEGFR2, KDR, Flk-1) is a major receptor for VEGF-induced signaling in endothelial cells. Upon ligand binding, VEGFR2 undergoes autophosphorylation and becomes activated (1). Major autophosphorylation sites of VEGFR2 are located in the kinase insert domain (Tyr951/996) and in the tyrosine kinase catalytic domain (Tyr1054/1059) (2). Activation of the receptor leads to rapid recruitment of adaptor proteins, including Shc, GRB2, PI3 kinase, NCK, and the protein tyrosine phosphatases SHP-1 and SHP-2 (3). Phosphorylation at Tyr1212 provides a docking site for GRB2 binding and phospho-Tyr1175 binds the p85 subunit of PI3 kinase and PLCgamma, as well as Shb (1,4,5). Signaling from VEGFR2 is necessary for the execution of VEGF-stimulated proliferation, chemotaxis and sprouting, as well as survival of cultured endothelial cells in vitro and angiogenesis in vivo (6-8).

Supporting Data

REACTIVITY	H M
SENSITIVITY	Endogenous
MW (kDa)	230
Source/Isotype	Rabbit IgG

Application Key:

W-Western
IP-Immunoprecipitation
IHC-Immunohistochemistry
ChIP-Chromatin Immunoprecipitation
IF-Immunofluorescence
F-Flow Cytometry
E-P-ELISA-Peptide

Species Cross-Reactivity Key:

H-Human
M-Mouse
R-Rat
Hm-Hamster
Mk-Monkey
Vir-Virus
Mi-Mink
C-Chicken
Dm-D. melanogaster
X-Xenopus
Z-Zebrafish
B-Bovine
Dg-Dog
Pg-Pig
Sc-S. cerevisiae
Ce-C. elegans
Hr-Horse
All-All Species Expected

Product Usage Information

Application	Dilution
Western Blotting	1:1000
Immunohistochemistry (Paraffin)	1:50

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

Specificity / Sensitivity

Phospho-VEGF Receptor 2 (Tyr951) (15D2) Rabbit Monoclonal Antibody detects endogenous levels of VEGF receptor 2 only when phosphorylated at Tyr951. The antibody may slightly cross-react with activated VEGF receptor 1, but not with other related tyrosine phosphorylated tyrosine kinases.

Species Reactivity:

Human, Mouse

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr951 of human VEGF receptor 2.

Background

Vascular endothelial growth factor receptor 2 (VEGFR2, KDR, Flk-1) is a major receptor for VEGF-induced signaling in endothelial cells. Upon ligand binding, VEGFR2 undergoes autophosphorylation and becomes activated (1). Major autophosphorylation sites of VEGFR2 are located in the kinase insert domain (Tyr951/996) and in the tyrosine kinase catalytic domain (Tyr1054/1059) (2). Activation of the receptor leads to rapid recruitment of adaptor proteins, including Shc, GRB2, PI3 kinase, NCK, and the protein tyrosine phosphatases SHP-1 and SHP-2 (3). Phosphorylation at Tyr1212 provides a docking site for GRB2 binding and phospho-Tyr1175 binds the p85 subunit of PI3 kinase and PLCγ, as well as Shb (1,4,5). Signaling from VEGFR2 is necessary for the execution of VEGF-stimulated proliferation, chemotaxis and sprouting, as well as survival of cultured endothelial cells in vitro and angiogenesis in vivo (6-8).

Meyer, M. et al. (1999) EMBO J 18, 363-74.
Dougher-Vermazen, M. et al. (1994) Biochem Biophys Res Commun 205, 728-38.
Kroll, J. and Waltenberger, J. (1997) J Biol Chem 272, 32521-7.
Takahashi, T. et al. (2001) EMBO J 20, 2768-78.
Holmqvist, K. et al. (2004) J Biol Chem 279, 22267-75.
Karkkainen, M.J. and Petrova, T.V. (2000) Oncogene 19, 5598-605.
Rahimi, N. et al. (2000) J Biol Chem 275, 16986-92.
Claesson-Welsh, L. (2003) Biochem Soc Trans 31, 20-4.